CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 — Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells. [Read more…]
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Dr. Robert Hariri – Placental Pioneer Launches Celularity with $250M Cash
Dr. Robert Hariri is a fascinating figure in the stem cell industry, because he was the earliest pioneer to recognize the regenerative potential of the human placenta. In August 2017, Hariri brought his latest company, Celularity, into the spotlight by announcing a successful Series A financing with contributions from influential investors, including United Therapeutics Corporation, Celgene, Sorrento Therapeutics, and Human Longevity, Inc. (HLI).
Today, Celularity’s investor contributions have reached an astounding $250 million, including contributions from the Genting Group, Dreyfus Family Office and Tony Robbins, among other notable investors. [Read more…]
Ciloa’s project among the 11 winners of the “Sanofi iTech Awards”
-
French biotech company Ciloa wins the 2020 “Sanofi iTech Awards”.
-
The winning project is based on the unique innovation developed by Ciloa, which uses its customized exosomes for therapeutic purposes.
-
The “Sanofi iTech Awards” program funds and supports projects related to the development of innovative technologies in Healthcare that may lead to a subsequent research collaboration between Sanofi and Ciloa.
Nucleus Biologics Launches Artificial Intelligence Research (NB-AIR): The World’s First AI Platform for Media Configuration That Gives Control Back To The Scientists
SAN DIEGO, Feb. 9, 2021 — Nucleus Biologics™, The Cell Performance Company™, today announced the availability of NB-AIR™, the world’s first Artificial Intelligence Research platform for optimizing cell culture formulations for cell and gene therapies. Leveraging cutting-edge AI algorithms, the system empowers scientists to create optimized formulas based on meta-analysis of peer-reviewed articles. AI guided formulations will allow scientists to improve the performance of their cell therapy and shorten the time to get these lifesaving therapies into patients faster. [Read more…]
LifePlus Stem Cells Delivers its First Allogeneic Mesenchymal Stem Cells for the Treatment of Arthritis
LifePlus Stem Cells, a provider of innovative stem cell advancements, specialising in regenerative rehabilitation announces their first injection of its umbilical cord-derived allogeneic mesenchymal stem cells. Using a unique and highly regulated manufacturing process, LifePlus Stem Cells is able to provide patients and clinicians with the world’s purest allogeneic mesenchymal stem cells – achieving purity levels of well over 80%.
- « Previous Page
- 1
- …
- 89
- 90
- 91
- 92
- 93
- …
- 146
- Next Page »